Subsequent Events |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Subsequent Events [Abstract] | |
| Subsequent Events |
19. Subsequent Events
In accordance with ASC 855, Subsequent Events, the Company evaluated subsequent events after September 30, 2026, through the date these condensed consolidated financial statements were issued and has determined that, other than already disclosed or noted below, no further transactions or events have occurred that require recognition or disclosure in the condensed consolidated financial statements.
Recapitalization and Proposed Merger
On November 10, 2026, the Company entered into and closed Note Amendment and Conversion Agreements with holders of approximately $14.1 million of the $14.9 million aggregate principal amount of its convertible notes. Effective immediately, and whether or not the merger described below is completed, the conversion price of the notes was reduced to $5.50 per share and the exercise price of the related warrants to $13.00 per share (in each case after giving effect to the Reverse Split described in Note 1). Upon completion of the merger and satisfaction of other conditions, the holders will convert their notes into common stock at $ per share and receive interest accrued through September 30, 2026 in common stock. If the merger is not completed by March 31, 2027 (subject to extension), the conversions will not occur, the notes will remain outstanding with interest reinstated from October 1, 2026, and the shares sold in the financing described below will be exchanged for convertible notes. Concurrently, the Company entered into a securities purchase agreement providing for the sale of up to $ million of shares of common stock at $ per share, each share accompanied by a warrant to purchase one share of common stock at an exercise price of $10.00 per share, and on November 10, 2026 issued shares of common stock and warrants to purchase 281,182 shares of common stock under that agreement for gross proceeds of approximately $1.2 million.
The proposed merger would combine the businesses of Fountainhead LifeSciences and its affiliates, including Sequence and NVISION Biomedical Technologies, Inc. (“Fountainhead”), with the Company in exchange for 45% to 50% of the Company’s fully diluted shares. Fountainhead is an affiliate of Mr. Kieser, the Company’s Interim Chief Executive Officer and a director, so the merger would be a related party transaction. Mr. Kieser, Sequence and certain other directors and officers hold notes and participated in the financing. No definitive agreement for the merger has been entered into, and there is no assurance that it will be completed. The Company is evaluating the accounting for these transactions, including the modification of the notes and warrants, and cannot yet estimate their effect on its financial statements.
Potential Sale of Consumer Brands
In October 2026, the Company began marketing its Silly George and Kenkoderm brands for sale. No definitive agreement has been entered into with respect to either or both brands, and the Company does not expect a sale to have a material effect on its results. |